Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

<p>Shows the persistence of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) in the peripheral blood of two out of four patients.</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Ulka N. Vaishampayan (15051039) (author)
Бусад зохиолчид:	Archana Thakur (15051042) (author), Wei Chen (15051045) (author), Abhinav Deol (15051048) (author), Meera Patel (15051051) (author), Kimberlee Dobson (15051054) (author), Brenda Dickow (15051057) (author), Dana Schalk (15051060) (author), Amy Schienschang (15051063) (author), Sarah Whitaker (15051066) (author), Amanda Polend (15051069) (author), Joseph A. Fontana (411960) (author), Elisabeth I. Heath (15024674) (author), Lawrence G. Lum (15051072) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
-н: Giuseppe Basile (15051269)
Хэвлэсэн: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
-н: Alexander N. Shoushtari (15023909)
Хэвлэсэн: (2025)

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
-н: Julio C. Chavez (15181310)
Хэвлэсэн: (2025)

Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
-н: Julio C. Chavez (15181310)
Хэвлэсэн: (2025)

Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
-н: Julio C. Chavez (15181310)
Хэвлэсэн: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
-н: Ibrahim Aldoss (15055961)
Хэвлэсэн: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
-н: Roger Li (17078665)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
-н: Ibrahim Aldoss (15055961)
Хэвлэсэн: (2025)

Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
-н: Ibrahim Aldoss (15055961)
Хэвлэсэн: (2025)

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
-н: Ibrahim Aldoss (15055961)
Хэвлэсэн: (2025)

Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
-н: Ibrahim Aldoss (15055961)
Хэвлэсэн: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
-н: Samuel Rosner (15054884)
Хэвлэсэн: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
-н: Amir T. Fathi (15313195)
Хэвлэсэн: (2025)

Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
-н: Wei Chen (15053713)
Хэвлэсэн: (2025)

Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
-н: Wei Chen (15053713)
Хэвлэсэн: (2025)

Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
-н: Wei Chen (15053713)
Хэвлэсэн: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
-н: Ruiyun Zhang (17142498)
Хэвлэсэн: (2025)

Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
-н: H. Josh Jang (15206898)
Хэвлэсэн: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
-н: Amir T. Fathi (15313195)
Хэвлэсэн: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
-н: Nam Q. Bui (14958210)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_g23u0thab45rqf6o7j10992fkq